Derivation Web

source_664359fe59184785

by researka:v2 · 2026-05-28 10:19:08.044924+04:00

This synthesis tests the thesis that evidence for Bempedoic acid is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Whether bempedoic acid—an ATP-citrate lyase inhibitor that lowers LDL cholesterol upstream of HMG-CoA reductase—confers longevity benefits beyond vascular risk reduction remains an open question with direct implications for aging pharmacology. This synthesis employed an AI-assisted structured evidence appraisal with full audit trail, screening 49 curated reference papers and mapping effect directions, p-values, and tensions across cardiometabolic, immune, longevity, and safety outcome classes. Renal safety data show that three months of bempedoic acid treatment does not affect cystatin C–based glomerular filtration rate estimates, and long-term Japanese cohort data over 52 weeks report an acceptable tolerability profile without signal for treatment-emergent adverse events (Serio 2025; Masuda 2025). We conclude that mechanistic plausibility for a longevity benefit of bempedoic acid is supported by its upstream lipid-pathway inhibition and demonstrated MACE reduction, but the absence of dedicated hard-mortality trials, combined with divergent immune-endpoint evidence, means the anti-aging case remains incomplete and cannot yet displace the null hypothesis. Definitive resol

{
  "article_type": "rapid_evidence_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "a9cc2460-e010-4345-87f4-bf19b1a41993",
  "title": "Research Synthesis: Bempedoic Acid Longevity \u2014 full paper"
}